PT
Insider
Philip Tsai
Chief Technology OfficerPhilip Tsai (Chief Technology Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Immunome, Inc. (IMNM). Across 1 priced purchase filing, the average 21-session return was +20.1% from execution and +17.6% from disclosure (delay-adjusted; derived). The largest single filing was $205K of IMNM (10,000 sh × $20.49, as filed), executed Dec 19 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+20.1%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+17.6%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$205K
shares × price, as filed
Last traded
Dec 19 2025
Filed Dec 22 2025
Median ADV $31.5M across their filed names
Open performance→Volume by month
Buys $506K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
IMNMRecent filings
IMNMPURCHASE
Immunome, Inc.
View filing →
$205K10,000 sh × $20.49
Exec Dec 19 2025
Filed Dec 22 2025 · 7:32 AM ET IMNMPURCHASE Immunome, Inc. View filing → $104K
12,300 sh × $8.42
Exec Mar 24 2025
Filed Mar 25 2025 · 5:30 PM ET IMNMPURCHASE Immunome, Inc. View filing → $198K
21,000 sh × $9.43
Exec Nov 21 2024
Filed Nov 25 2024 · 5:30 PM ET